Trials / Conditions / Stage IVA Lip and Oral Cavity Cancer AJCC v8

Stage IVA Lip and Oral Cavity Cancer AJCC v8

13 registered clinical trials studyying Stage IVA Lip and Oral Cavity Cancer AJCC v8 — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cann NCT07441681	NRG Oncology	Phase 3
Recruiting	Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Ca NCT07195734	National Cancer Institute (NCI)	Phase 2
Recruiting	Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN281 NCT06980038	National Cancer Institute (NCI)	Phase 2
Not Yet Recruiting	Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squ NCT07156227	National Cancer Institute (NCI)	Phase 1
Recruiting	Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Sq NCT07121595	University of Michigan Rogel Cancer Center	Phase 2
Recruiting	Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy f NCT06532279	NRG Oncology	Phase 2
Terminated	A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade NCT05316688	University of Washington	Phase 1 / Phase 2
Recruiting	Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer NCT05172245	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cance NCT04533750	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcin NCT04862650	Marcelo Bonomi	Phase 2
Completed	Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With NCT04541355	Hyunseok Kang, MD	Phase 2
Completed	Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck NCT03258554	National Cancer Institute (NCI)	Phase 2 / Phase 3
Recruiting	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of NCT02734537	ECOG-ACRIN Cancer Research Group	Phase 2